VREOFOTCPharmaceutical PreparationsFiscal year ends December 31
Vireo Growth Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$9.01+0.01 (+0.11%)
Close on Oct 19, 2026
- Market cap
- $406.23M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
47.3%+12.5 pts over 5 years
Operating margin
-0.4%+46.4 pts over 5 years
Net margin
-25.3%+21.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +170.4% | +53.3% | +40.4% | – | |
| Gross profit | +150.3% | +60.2% | +49.3% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -41.3% | -37.5% | |
| Return on assets | – | – | -12.4% | |
| Current ratio | – | 2.36 | 1.59 | |
| Debt to equity | – | 0.02 | – | |
| Net debt to EBITDA | – | 1.26× | – | |
| Interest coverage | – | -4.5× | – | |
| Inventory turnover | – | – | 3.5× | |
| Capex to revenue | – | 17.2% | 10.5% | |
| Diluted shares | – | 3M | 24M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vireo Growth generated $63.50M from operations and spent $68.59M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$63.50M
Used
$68.59M
Capital expenditure$68.59M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-25.3%
×Asset turnover0.49×
×Equity multiplier3.02×
=Return on equity, FY2025-37.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -25.3% | 0.49× | 3.02× | -37.5% |
| FY2024 | -28.2% | 0.43× | 11.71× | -142.0% |
| FY2023 | -29.0% | 0.51× | -27.17× | 405.4% |
| FY2022 | -56.9% | 0.46× | 7.02× | -182.8% |
| FY2021 | -61.9% | 0.40× | 2.56× | -64.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$68.11M
- Cash generatingOperating cash flow above zero$3.71M
- Return on assets improvedROA up on the prior year-15.3% → -24.4%
- Earnings backed by cashOperating cash flow above net income$3.71M vs -$68.11M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.70 → 1.59
- No dilutionShare count did not rise6M → 24M
- Gross margin improvedGross margin up on the prior year51.09% → 47.29%
- More efficientAsset turnover rose0.54 → 0.96